Earnings Releases·Nov 10, 2026, 4:36 PM ET

iBio — Q1 Fiscal Year 2027 Earnings Summary

Revenue increased to $1.1 million from $0.1 million year-over-year, while net loss widened to $7.6 million ($0.05 per share) from $5.7 million ($0.11 per share) in the prior year period.
Research and development expenses rose 87% to $6.7 million, driven by costs for IBIO-600 Phase 1 trials, NHP studies, and CMC activities.
The company anticipates an IND-equivalent filing for IBIO-610 by end of 2026, with first-in-human trials expected in H1 2027 and Phase 1 data for IBIO-600 anticipated in Q1 2027.
Cash and cash equivalents decreased to $45.4 million as of September 30, 2026, from $56.4 million at June 30, 2026, while weighted-average shares outstanding increased to 151.6 million from 53.0 million year-over-year.